Navigating Multiple Myeloma: From Newly Diagnosed to Relapsed/Refractory - Episode 2
Quadruplet Regimens as Front-Line Therapy for Newly Diagnosed Transplant-Ineligible Multiple Myeloma
Panelists discuss how recent trials evaluating quadruplet regimens in transplant-ineligible/deferred NDMM, including IMROZ and BENEFIT, demonstrate promising efficacy with isatuximab-VRd combinations showing comparable MRD negativity rates to CEPHEUS’ daratumumab-VRd data, though cross-trial comparisons require careful interpretation.
Video Player is loading.
Video content above is prompted by the following:
- Please comment on other quadruplet regimens in the TIE or deferred NDMM space.
- Briefly discuss IMROZ(isatuximab [Isa]-VRd vs VRd)
- IMROZ, MRD negativity
- Briefly discuss BENEFIT (Isa-VRd vs Isa-Rd)
- Thinking back to CEPHEUS, how do data from these trials compare?
